{"id":12,"date":"2019-11-27T14:25:24","date_gmt":"2019-11-27T14:25:24","guid":{"rendered":"https:\/\/zobio.com\/online\/?page_id=12"},"modified":"2026-04-02T10:13:31","modified_gmt":"2026-04-02T10:13:31","slug":"case-studies","status":"publish","type":"page","link":"https:\/\/zobio.com\/online\/case-studies\/","title":{"rendered":"Case studies"},"content":{"rendered":"
\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>

Case Studies<\/h2>\n
\n\t

ZoBio has addressed more than 120 targets and worked on therapeutic areas including central nervous system disorders, oncology, inflammation and metabolic disease.\u00a0<\/s><\/span><\/p>\n

In addition to classic active site inhibitors, we have been tasked with developing allosteric modulators and pharmacologic chaperones. The core approach of fragments and biophysics has led to the successful completion of many projects on a diverse array of targets such as phosphodiesterases, kinases, proteases, phosphatases and protein-protein interactions (PPIs). <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t

We\u2019ve also applied our approach to particularly challenging targets such as ubiquitin metabolism enzymes (deubiquitinases and E3 ligases) and epigenetic and epitranscriptomic targets.<\/p>\n

Here you can find examples demonstrating how we successfully enabled FBDD campaigns on challenging targets<\/span>.<\/p>\n<\/div>\n<\/div><\/div><\/div>

\n
\n\t

Get in contact<\/a><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>

\n
\n\t\n\t
\n\t\t\n\t\t\t\"PRMT5:\t\t<\/a>\n\n\t\t<\/div>\n\t\n\t
\t\n\t\t
\n\t\t\t

PRMT5: Capturing Out-of-Range Target Engagement Kinetics for an Advanceable Clinical Candidate<\/a><\/h2>\t\t\t\t\t<\/header>\n\t\n\t\t
\n\t\t\t

Challenge<\/b>
\nOur client requested characterization of the oncology clinical candidate MRTX1719\u2019s interaction with two forms of Protein Arginine Methyl Transferase 5 (PRMT5), bound to either SAM (PRMT5\u2022SAM) or MTA (PRMT5\u2022MTA).
\nSPR (Surface Plasmon Resonance) direct measurement was not feasible due to the slow dissociation rate (koff) of MRTX1719 from both PRMT5 complexes. The dissociation rate was too slow, causing minimal dissociation during single-cycle kinetics, which prevented accurate koff determination.
\nAchievements<\/b>
\nTo overcome this problem an adapted SPR chaser assay was implemented. This strategy indirectly measured the dissociation rate constant (koff) and allowed for the determination of the affinity of MRTX1719 for both complexes.<\/p>\n\n\t